



There are many gaps in our knowledge about MS that need to be answered using real-world data



How can we diagnose better and earlier?

What affects disease evolution?



How does memory loss relate with disability?

Does an increase of 0.5 in EDSS mean that this person is deteriorating?



How effective are treatments in a real-world setting? (e.g. pregnancy, aging, treatment switch, combined treatments, long-term, ...)

Is one treatment more effective compared to another?



How safe and tolerable are our treatments in a real-world setting? (e.g. pregnancy, aging, treatment switch, combined treatments, long-term, ...)



Objectives of the meeting



To <u>inform</u> different stakeholders about our mission, vision and strategic focus areas of the MS Data Alliance initiative



To <u>engage</u> different stakeholders to be involved in the MS Data Alliance initiative



MSDA Stakeholders - Participants Stakeholder Meeting

e.g. RIMS, International MS Genetic Consortium, EAN, ACTRIMS, RUCTRIMS, Progressive MS Alliance, MS BrainHealth, Consortium of MS Centers, ParadigMS, Big MS Data Network, European Health Data and Evidende Network...

Researchers Regulatory decision-makers People with MS / patient societies Clinicians Industry Data custodians

e.g. European Medicine Agency, BeNeLuxA initiative (=Health Technology Assessment)

e.g. European MS Platform, MS International Federation, European Patients Forum, United States, Italy, Ireland, Spain, Serbia, Portugal, Denmark, Greece, Belgium, Romania, France, ...

e.g. German MS Registry, UK MS Registry,
MSBase Registry, Swedish MS Registry, Danish
MS Registy, Italian MS Registry, OptimiseMS,
RevelarEM, IconquerMS, Accelerated Cure Project
for MS, NeuroTransData, PROMOPROMS,
Spanish MS Registry, MultipleMS, German
Pregnancy Registry, NARCRMS, CEMCAT CIS
Cohort, Canadian Progression Cohort in MS,
Greek Registry, NARCOMS, British Columbia MS
Database, Australian MS Longitudinal Study, Swiss
Cohort Study, Swiss MS Registry, Norwegian MS
Registry, BELTRIMS, MSDS3D, ...

e.g. European Federation of Pharmaceutical Industries and Associations, Novartis, Merck, Biogen, Icometrix, Quanterix, Qmenta, Canopy Growth Corporation, Mylan, Janssen, Celgene, ...



MSDA Stakeholders – Participants Stakeholder Meeting



